Companies › Annovis Bio
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| buntanetap | – | Phase 3 | Early Alzheimers Disease; Parkinson's Disease (PD) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06709014 | buntanetap | Phase 3 | Early Alzheimers Disease | Neurology | Dec 2027 |
| NCT07284784 | buntanetap | Phase 2 | Parkinson's Disease (PD) | Neurology | Sep 2029 |
Cash of $19m on 2026-06-30; operating cash outflow about $63m a year; runway about 4 months at that burn, to Oct 2026; 0 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Biohaven Pharmaceuticals Larimar Therapeutics Immunic Alpha Cognition NervGen Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.